H63D Syndrome E-Book

Sven Sörensen

• Herausgeber: Books on Demand
• Kategorie: Ratgeber
• Sprache: Englisch

Seitenzahl: 19

Veröffentlichungsjahr: 2020

Beschreibung

Oslo Syndrome (in research still known as H63D Syndrome) is a worldwide health problem in the field of iron metabolism disorders. After scientists from all over the world joined together in 2019 to form the H63D Syndrome Consortium, the consensus paper "H63D Syndrome" was adopted at a meeting in Oslo in December 2019. On the occasion of the 2022 conference the syndrome was renamed Oslo Syndrome for clinical settings. It is available in bookshops for a symbolic price. Also free of charge directly from the consortium.

Leseprobe

H63D Syndrome

The H63D Syndrom Research Consortium and associated InstitutionsPrefaceOslo Syndrome (H63D syndrome for research purposes)Important information for laymenDisclaimerStudies et al. (some of many)Copyright

The H63D Syndrom Research Consortium and associated Institutions

Knowing that research on H63D Syndrome (Oslo Syndrome as of 2022) as a rare disease will never be funded by large corporations, we established an international scientific non-profit consortium many years ago. In the past decade, a network to other working groups has been established, which has considerably expanded and enriched the scientific basis of the work on the phenomenon "H63D Syndrome" in terms of both personnel and research results. The goal of our work at the highest clinical level is to further research the syndrome and to make this knowledge available to the public. Although H63D/Oslo Syndrome is a rare disease, with over seven billion people on earth it is a disease with high case numbers. It is also a condition that far too few doctors know about, although it is not difficult to be understood, and in many ways it is similar to Wilson's disease, with the difference that here iron is the culprit, not copper.

During the H63D conference in 2022, the expanded state of knowledge could once again be summarized to ensure that all active working groups worldwide are on the same level of research. In addition, it was decided to assign a second name to H63D syndrome, which is more memorable for clinicians and easier to use in everyday medical practice. In reference to the many working groups that have repeatedly met in Oslo (Norway) over the years, the name "Oslo Syndrome" was chosen by consensus of all entities involved.

On behalf of all institutions contributing,

Dr. Lucas Smith

January 2022

Preface

Oslo Syndrome (H63D syndrome for research purposes) is a systemic disease due to oxidative processes caused by NTBI overload (NTBI-siderosis) in vulnerable body cells of patients with a homozygous mutation in HFE gene H63D which can lead to organ dysfunction and severe organ damage.